Devgen finalises nematicide trials
Belgian biotechnology company Devgen (Ghent) has finalised the necessary regulatory trials with its lead nematicide compound and is compiling the first regulatory dossiers for product registration in the US and southern Europe. It expects dossier compilation to be completed by the end of the year. Other preparations for production and distribution are also on track, the company says. It expects its first nematicide sales in 2010.